Abstract
Until now it is still not clear which structural elements of the prion protein (PrP) are involved in its conversion process. Characterisation of these essential regions would help to understand the conversion process itself and might help to develop specific therapeutic approaches to inhibit PrPres formation by dominant inhibitory mutations. To address this important question 33 evenly spaced insertion mutants were generated spanning the entire sequence of the murine 3F4- tagged PrP. The mutants were expressed by retroviral transduction in three different scrapie infected cell lines (ScN2a; SMB[RC040]; SMB[22F]). The convertibility was affected not only by introducing the insertion in the putatively refolded region (aa100-170), but also in the C-terminus of PrP (up to aa214). Moreover, dominant inhibitory effects on conversion were observed for PrP-mutants at four distinguished regions (aa100-112; aa130-154; aa166-172, aa196-200). Computer based structural analysis revealed that these segments were organized in two structurally clearly separated regions supporting the idea that they could function as protein-protein interaction sites which are necessary during seed formation.
Keywords: PrP mutants, PrP conversion, Glycosylation and cellular trafficking, PrP seed formation
Infectious Disorders - Drug Targets
Title: Inhibition of Prion Amplification by Expression of Dominant Inhibitory Mutants - A Systematic Insertion Mutagenesis Study
Volume: 9 Issue: 1
Author(s): Markus Geissen, Harriet Mella, Armin Saalmuller, Martin Eiden, Juliane Proft, Eberhard Pfaff, Hermann M. Schatzl and Martin H. Groschup
Affiliation:
Keywords: PrP mutants, PrP conversion, Glycosylation and cellular trafficking, PrP seed formation
Abstract: Until now it is still not clear which structural elements of the prion protein (PrP) are involved in its conversion process. Characterisation of these essential regions would help to understand the conversion process itself and might help to develop specific therapeutic approaches to inhibit PrPres formation by dominant inhibitory mutations. To address this important question 33 evenly spaced insertion mutants were generated spanning the entire sequence of the murine 3F4- tagged PrP. The mutants were expressed by retroviral transduction in three different scrapie infected cell lines (ScN2a; SMB[RC040]; SMB[22F]). The convertibility was affected not only by introducing the insertion in the putatively refolded region (aa100-170), but also in the C-terminus of PrP (up to aa214). Moreover, dominant inhibitory effects on conversion were observed for PrP-mutants at four distinguished regions (aa100-112; aa130-154; aa166-172, aa196-200). Computer based structural analysis revealed that these segments were organized in two structurally clearly separated regions supporting the idea that they could function as protein-protein interaction sites which are necessary during seed formation.
Export Options
About this article
Cite this article as:
Geissen Markus, Mella Harriet, Saalmuller Armin, Eiden Martin, Proft Juliane, Pfaff Eberhard, Schatzl M. Hermann and Groschup H. Martin, Inhibition of Prion Amplification by Expression of Dominant Inhibitory Mutants - A Systematic Insertion Mutagenesis Study, Infectious Disorders - Drug Targets 2009; 9 (1) . https://dx.doi.org/10.2174/1871526510909010040
DOI https://dx.doi.org/10.2174/1871526510909010040 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Leptin as a Novel Therapeutic Target for Immune Intervention
Current Drug Targets - Inflammation & Allergy Role of Nitric Oxide in the Modulation of Angiogenesis
Current Pharmaceutical Design [1, 2, 4]-Oxadiazoles: Synthesis and Biological Applications
Mini-Reviews in Medicinal Chemistry Severe Influenza: Clinical Features and Treatment Options
Current Respiratory Medicine Reviews Targeting Kynurenine 3-Monooxygenase (KMO): Implications for Therapy in Huntingtons Disease
CNS & Neurological Disorders - Drug Targets The Chemokine CXCL10 as a Therapeutic Target in Animal Models of Neuroinflammatory Disease
Letters in Drug Design & Discovery Bioactive Bacterial Components: Could they Change the Probiotic World?
Current Bioactive Compounds The Therapeutic Potential of Cell-Internalizing Aptamers
Current Topics in Medicinal Chemistry p53-Induced Apoptosis and Inhibitors of p53
Current Medicinal Chemistry Role of Adenosine Receptors in Rare Neurodegenerative Diseases with Motor Symptoms
Current Protein & Peptide Science Stem Cell-Like Brain Cancer Cells
Current Cancer Therapy Reviews Adverse Events of Proton Pump Inhibitors: Potential Mechanisms
Current Drug Metabolism Perspectives and New Aspects of Metalloproteinases’ Inhibitors in the Therapy of CNS Disorders: From Chemistry to Medicine
Current Medicinal Chemistry Osteoimmunology and Beyond
Current Medicinal Chemistry Patent Selections:
Recent Patents on Anti-Infective Drug Discovery What We have Learned about Pain from Rodent Models of Arthritis?
Current Rheumatology Reviews Coreceptor Switch in Infection of Nonhuman Primates
Current HIV Research Genetics of Bladder Malignant Tumors in Childhood
Current Genomics Recent Advances in Phenanthroindolizidine and Phenanthroquinolizidine Derivatives with Anticancer Activities
Anti-Cancer Agents in Medicinal Chemistry Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases
Current Drug Targets